Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market Intelligence.
Investors waiting to find out what Gilead Sciences would do with the tens of billions of dollars in its balance sheet were rewarded when the company announced it will be acquiring Kite Pharma (NASDAQ: KITE) in a deal valued at nearly $12 billion in cash.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Gilead Sciences Inc Aktie
Eine klare Neigung zu Buy-Einschätzungen bei Gilead Sciences Inc, ohne Sell-Einschätzungen.
Ein Kursziel von 85 € für Gilead Sciences Inc zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 71.02 €.